The clinical-stage Clene Nanomedicine Firm Reported Significantly Decreased Mortality in Amyotrophic Lateral Sclerosis (ALS)

CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs 14 placebo deaths

CNM-Au8 treatment was well-tolerated, with no significant safety findings  during this trial
Clene Inc in the NEWS
Clene Inc (CLNN), along with its subsidiaries, “Clene”, and its wholly owned . . .